Stereotactic Body Radiation (SBRT)

RADIATION3 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)OligometastasesPancreatic CancerPancreatic Ductal Adenocarcinoma

Phase 1

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

CompletedNCT03767582

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLocally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma

Start: 2019-12-12End: 2025-02-01Updated: 2025-12-03

Phase 2

Stereotactic Body Radiation With Nelfinavir for Oligometastases

CompletedNCT01728779

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOligometastases

Start: 2014-01-08End: 2020-12-31Updated: 2021-07-12

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

CompletedNCT03161379

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2018-02-02End: 2024-02-28Updated: 2025-02-03

Related Papers

Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).

Journal of Clinical Oncology2023-06-016 citations

Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.

Journal of Clinical Oncology2023-01-2421 citations

Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)

Cancer Research2019-07-011 citations

Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)

Clinical Trials2019-07-01